Want to see ALMS full AI Analyst Report?
Top Page
Alumis Inc.
(NASDAQ:ALMS)
Select Model
Select Model
Rating:59Neutral
Price Target:
$28.00
▲(12.04% Upside)
Action:Reiterated
Date:06/29/26
The score is held back primarily by weak financial performance (steep revenue decline, large losses, and heavy cash burn), despite a supportive low-leverage balance sheet. Offsetting this, technicals are strong with the stock trading above key moving averages and positive momentum, and recent corporate events highlight encouraging Phase 3 data and forthcoming milestones. Valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Phase 3 efficacy
Robust, replicable Phase 3 skin‑clearance outcomes with favorable safety materially de‑risk the lead program. Durable clinical efficacy supports a U.S. filing, strengthens labeling potential and underpins long‑term commercial positioning in oral immunology, improving odds of future revenue conversion and partner interest.
Negative Factors
Heavy cash burn
Sustained, large negative operating and free cash flow creates structural liquidity pressure and makes the company reliant on external financing or partnerships. Over the medium term this increases dilution risk, can constrain R&D sequencing, and forces near‑term strategic financing decisions regardless of trial outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 efficacy
Robust, replicable Phase 3 skin‑clearance outcomes with favorable safety materially de‑risk the lead program. Durable clinical efficacy supports a U.S. filing, strengthens labeling potential and underpins long‑term commercial positioning in oral immunology, improving odds of future revenue conversion and partner interest.
Read all positive factors
Alumis Inc. (ALMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.40B
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)-1.39
Revenue Growth-51.68%
EPS Growth69.60%
CountryUS
Employees223
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.91
Shares Outstanding123,432,076
10 Day Avg. Volume1,545,199
30 Day Avg. Volume1,133,995
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue335.26
Enterprise Value/Gross Profit374.04
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$40.00Price Target Upside60.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$7.82M
Alumis Inc. Business Overview & Revenue Model
Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque ps...
How the Company Makes Money
null...
Alumis Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.40M | 24.05M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.53M | 20.55M | -3.15M | 0.00 | -250.00K |
| EBITDA | -414.05M | -248.39M | -291.08M | -153.71M | -111.68M |
| Net Income | -237.41M | -243.32M | -294.23M | -154.99M | -111.93M |
Balance Sheet | |||||
| Total Assets | 671.59M | 411.94M | 340.99M | 89.61M | 108.17M |
| Cash, Cash Equivalents and Short-Term Investments | 522.94M | 308.50M | 288.26M | 48.95M | 92.86M |
| Total Debt | 35.66M | 36.91M | 30.72M | 32.58M | 1.78M |
| Total Liabilities | 104.57M | 110.64M | 80.89M | 428.87M | 303.41M |
| Stockholders Equity | 567.02M | 301.30M | 260.10M | -339.26M | -195.24M |
Cash Flow | |||||
| Free Cash Flow | -377.03M | -370.18M | -256.81M | -134.47M | -110.13M |
| Operating Cash Flow | -376.25M | -369.52M | -255.08M | -129.97M | -107.72M |
| Investing Cash Flow | -37.24M | 287.88M | -113.79M | 60.47M | -68.75M |
| Financing Cash Flow | 349.06M | 2.07M | 492.37M | 89.68M | 101.63M |
Alumis Inc. Technical Analysis
Positive
24.99
Price Trends
23.32
Positive
24.48
Positive
17.45
Positive
Market Momentum
1.28
Negative
63.30
Neutral
84.53
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALMS, the sentiment is Positive. The current price of 24.99 is above the 20-day moving average (MA) of 23.14, above the 50-day MA of 23.32, and above the 200-day MA of 17.45, indicating a bullish trend. The MACD of 1.28 indicates Negative momentum. The RSI at 63.30 is Neutral, neither overbought nor oversold. The STOCH value of 84.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALMS.
Alumis Inc. Risk Analysis
Alumis Inc. disclosed 78 risk factors in its most recent earnings report. Alumis Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alumis Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.88B | -13.39 | -63.58% | ― | -61.87% | 10.39% | |
59 Neutral | $3.40B | -13.95 | -54.63% | ― | -51.68% | 69.60% | |
52 Neutral | $401.90M | ― | -128.53% | ― | 928.46% | -21.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $145.00M | -1.08 | 65.27% | ― | 4.43% | 27.41% |
* Healthcare Sector Average
ALMS
Alumis Inc.
26.64
23.24
683.53%
AUTL
Autolus Therapeutics
1.58
-0.79
-33.33%
ADCT
ADC Therapeutics
1.14
-1.71
-60.00%
ABSI
AbSci
11.11
8.34
301.08%
Alumis Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Alumis Highlights TYK2 Strategy in Updated Investor Presentation
Positive
Jun 29, 2026
On June 29, 2026, Alumis Inc. updated its corporate presentation for investors and analysts, highlighting its strategy to transform treatment of immune-mediated diseases with next-generation TYK2 inhibitors envudeucitinib and A-005. The company em...
Business Operations and StrategyProduct-Related Announcements
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
Positive
Mar 30, 2026
On March 28, 2026, Alumis reported Phase 3 data from its ONWARD1 and ONWARD2 trials showing that envudeucitinib, its oral TYK2 inhibitor, delivered rapid and robust skin clearance and symptom relief in adults with moderate-to-severe plaque psorias...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.